Corxel Pharmaceuticals secures USD287M to advance its oral weight loss drug pipeline.

CHINA—China-based Corxel Pharmaceuticals has secured USD 287 million in a Series D1 financing round, demonstrating that investor enthusiasm for weight loss drug development remains robust.

The substantial funding round attracted several new investors, including SR One, TCGX, and RA Capital Management, while existing backers RTW Investments and Hengdian Group Capital also contributed to the raise.

The company plans to direct the capital primarily toward advancing its lead asset, CX11, an oral glucagon-like peptide-1 receptor agonist designed to help patients manage obesity and excess weight.

Unlike many weight loss medications that require injections, CX11 comes in pill form, potentially offering patients a more convenient treatment option.

The drug currently sits at different stages of clinical testing across two major markets, with a Phase II trial underway in the United States and a Phase III trial running concurrently in China, both evaluating the medication in obese and overweight individuals.

Corxel manages the American study directly, while Chinese biotech Vincentage oversees the Chinese trial.

The partnership between these companies stems from a late 2024 licensing agreement in which Corxel obtained worldwide rights to CX11, excluding China, from Vincentage.

 This arrangement allows both companies to pursue development in their respective territories while sharing the potential benefits of a successful drug launch.

Early clinical results have generated optimism about CX11’s potential effectiveness.

 At the 85th American Diabetes Association Scientific Sessions in June 2025, researchers presented Phase II data showing that patients taking the highest dose of CX11 with fast titration lost an average of 9.7 percent of their body weight over a 16-week period.

These findings have helped build confidence among investors and stakeholders in the drug’s commercial prospects.

The Series D1 proceeds will support several specific initiatives beyond the ongoing US trial.

Corxel intends to launch a Phase II study evaluating CX11 in patients with type 2 diabetes, a population that often struggles with weight management alongside blood sugar control.

The company will also begin preliminary preparations for Phase III trials, which typically represent the final testing stage before seeking regulatory approval for market entry.

Beyond its lead weight loss candidate, Corxel maintains a diverse pipeline of cardiometabolic therapies that will benefit from the new funding.

The company develops JX10, a pro-thrombolytic and anti-inflammatory drug candidate targeting acute ischemic stroke, a serious condition that occurs when blood flow to the brain becomes blocked.

Additionally, Corxel advances JX09, an aldosterone synthase inhibitor designed to treat hypertension by targeting a specific enzyme involved in blood pressure regulation.

Sandy Mou, who serves as Corxel’s chief executive officer, characterized the financing as a transformative moment for the organization.

The investment not only provides resources to accelerate global development of treatments for cardiometabolic diseases but also positions the company for significant expansion, according to Mou’s statement.

Corxel joins a growing list of obesity-focused biotechnology companies that have attracted substantial venture capital in recent months.

In October 2025, Kailera raised USD600 million in a Series B round to fund Phase III testing of KAI-9531, an injectable dual GLP-1/GIP receptor agonist.

Similarly, Metsera raised more than USD500 million across multiple funding rounds within just seven months in 2024, before Pfizer acquired the company in a USD10 billion transaction that followed competitive bidding against Novo Nordisk.

The robust investment activity reflects market projections showing tremendous growth potential.

 Analysts at GlobalData forecast that the obesity market across seven major markets—the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan—will reach USD173.5 billion by 2031.

Pharmaceutical giants Eli Lilly and Novo Nordisk currently dominate the global weight-loss market with their respective blockbuster medications, tirzepatide and semaglutide.

In December 2025, Novo Nordisk achieved a significant regulatory milestone by securing the first US approval for an oral GLP-1 receptor agonist specifically indicated for weight management, further validating the oral delivery approach Corxel pursues